The massive ~51% dilution from this offering will pressure the stock near-term. Monitor the stock for potential further downside as the market absorbs the new shares. The cash runway extension into mid-2027 is positive for the pipeline, but the dilution overhang and lack of near-term revenue catalysts suggest continued weakness.
Price Chart
Executive Summary
Cabaletta Bio priced a $150M underwritten offering of 51.7M shares at $2.90/share, representing ~51% dilution from the prior ~100.5M shares outstanding. The filing also disclosed a preliminary cash balance of ~$117M as of March 31, 2026, and the company reported Q4 2025 EPS of -$0.40, a 3.1% miss vs consensus of -$0.39. The capital raise extends the cash runway into mid-2027 to fund clinical development of rese-cel, but the massive dilution and lack of revenue fundamentally overshadow the pipeline progress.
Key Financial Metrics
Key Facts
- Priced underwritten offering of 51,725,000 shares at $2.90 per share, raising ~$150M in gross proceeds (~$141M net)
- Offering represents ~51% increase in shares outstanding from ~100.5M to ~152.2M shares
- Q4 2025 EPS of -$0.40 missed consensus of -$0.39 by 3.1%
- Preliminary cash balance of ~$117M as of March 31, 2026
- Net proceeds extend cash runway into mid-2027 for rese-cel clinical development and manufacturing scale-up
- No revenue reported; company is a pre-commercial biotechnology firm
Financial Impact
~$141M net proceeds from offering; ~51% dilution; Q4 2025 net loss of $41.9M
Risk Factors
- Immediate and significant dilution of ~51% from the offering
- No revenue and ongoing operating losses; net loss of $167.9M in FY2025
- Clinical-stage risk; rese-cel may fail in pivotal trials or face regulatory delays
- Cash runway only into mid-2027; may require additional capital before reaching profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202446 |
| Document: d145767dex992.htm | 0001193125-26-202446 |
| Document: d145767d8k.htm | 0001193125-26-202446 |
| Document: d145767dex991.htm | 0001193125-26-202446 |
| Document: d145767dex51.htm | 0001193125-26-202446 |
| Document: 0001193125-26-202446-index-headers.html | 0001193125-26-202446 |
| Document: 0001193125-26-202446-index.html | 0001193125-26-202446 |
| Document: 0001193125-26-202446.txt | 0001193125-26-202446 |
| 8-K Data (Synthetic) | 0001193125-26-202446 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access